Partial Opioid Agonist/Antagonist Drug Class List

Drugs in Drug Class: Partial Opioid Agonist/Antagonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	074736-001	Jan 21, 1997	AB	RX	No	Yes
Lupin	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	075735-001	Jul 11, 2001	AB	RX	No	No
Sun Pharm Inds Ltd	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	075523-001	Mar 17, 2000	AB	RX	No	No

Last updated: July 28, 2026

Partial Opioid Agonist/Antagonist market dynamics and patent landscape: What matters for exclusivity, Paragraph IV risk, and generic entry

Partial opioid agonist/antagonists (POAAs) anchor a large share of treated opioid-use disorder (OUD) and opioid-analgesia support. The patent landscape is typically split between: (i) long-running “platform” patents covering prodrugs, fixed-dose combinations, and extended-release (ER) delivery systems; (ii) newer patents on abuse-deterrent formulations (ADF), solubility/PK improvements, and manufacturing; and (iii) method-of-use patents tied to dosing regimens, induction, and special populations. Market dynamics are dominated by payer coverage of branded OUD medicines, government program tendering, REMS friction for certain products, and the timing of patent and exclusivity cliffs that drive generic and authorized generic launches.

This report covers the most commercially relevant POAAs: buprenorphine (single entity and combinations), buprenorphine/naloxone, and naltrexone formulations used in OUD and opioid dependence. It maps the exclusivity and patent-expiry drivers that govern competitive entry and provides litigation- and Orange-Book-driven guidance on where Paragraph IV risk concentrates.

---

Which partial opioid agonist antagonist drugs drive today’s market share and patent filings?

The POAA category in practice is led by buprenorphine-based OUD therapies and naltrexone-based antagonist therapies (used clinically for OUD relapse prevention and, in some settings, for opioid dependence treatment). The core branded products below concentrate commercial and patent activity.

Buprenorphine-based OUD medicines (core POAA market)

• Sublingual buprenorphine (branded and generics): typically used for induction and maintenance.
• Buprenorphine/naloxone combination (sublingual and film/tablet forms): the dominant OUD maintenance regimen in many geographies.
• Extended-release depot buprenorphine: supports monthly or less-frequent dosing, with ADF and formulation-heavy patent estates.

Naltrexone-based antagonist medicines (closely traded against POAA regimens)

• Extended-release naltrexone (injectable): competes with buprenorphine maintenance on adherence and relapse prevention.
• Oral naltrexone: older and more genericized in many markets, with limited blockbuster patent activity.

---

How do exclusivity and patent expiration timelines shape POAA competition and revenue exposure?

POAA competition is governed by two parallel clocks: (1) patent expiration (often formulation and method patents) and (2) data exclusivity periods for FDA reference-listed drug (RLD) products. For OUD medicines, the branded revenue curve often stays strong through the “last relevant Orange Book patent” and through formulary placement, even when some earlier patents lapse.

Typical timing drivers in POAA estates

• Orange Book “last patent”: generic entry risk increases after the last listed patent expires or becomes carve-out limited via a successful Paragraph IV.
• Pediatric exclusivity: can extend patent life for qualifying listed patents by up to 6 months (product- and patent-specific).
• Orphan drug exclusivity (if applicable): extends for eligible indications.
• Market access and REMS: REMS can indirectly affect generic adoption speed even when legal exclusivity ends.

Asset-level timing structure (what investors track)

For POAAs, the key questions for competitive entry are:

• Which listed patents are composition of matter vs formulation vs method-of-use?
• Which patents control particular dosage forms (film vs tablet vs ER implant vs injectable)?
• Which products have ADF-specific patents that generics cannot easily “design around”?

---

What patents protect buprenorphine and buprenorphine/naloxone products in the Orange Book?

POAA patent estates tend to be formulation-intensive. The most common protectable innovations include:

• Extended-release technologies (injectables, implants, depots)
• Mucoadhesive films and sublingual delivery systems (for buprenorphine and combination products)
• Abuse-deterrent approaches (physical or chemical barriers)
• Salt forms, polymorphs, and particle engineering
• Manufacturing methods that lock process-control parameters and impurity profiles
• Dosing regimen patents (induction/maintenance regimens, dose titration schedules, frequency)

Patent categories that usually matter most for generic design-around

1. Formulation patents that define excipient systems, coating structures, gel matrices, or polymer blends.
2. ER delivery and depot geometry/biopharmaceutics patents that tie PK profile to product-specific performance.
3. Method-of-use patents tied to OUD treatment algorithms or special populations.
4. Controlled manufacturing and impurity specifications that limit copying without inheriting breach risk.

---

When does partial opioid agonist antagonist exclusivity end for buprenorphine films, tablets, and depot injections?

Featured-snippet answer format for decision screens:

Exclusivity ends when both:

1. the last Orange Book patent covering the specific dosage form and indication expires (or is found not infringed/not valid via Paragraph IV litigation), and
2. any additional statutory exclusivities (data exclusivity, pediatric exclusivity, orphan exclusivity if applicable) have been satisfied for the relevant FDA approval.

In POAAs, the “last patent” is often not the earliest composition-of-matter patent, but a late-listed formulation, ADF, or depot-release patent. This drives the common pattern: early generic introductions occur for older dosage forms, while depot/ER products and specific ADF variants maintain brand pricing longer.

---

How many Orange Book patents cover each major POAA drug product and dosage form?

POAA coverage is usually broad for branded sublingual and depot products and lighter for older single-ingredient oral generics. The highest patent density typically appears on:

• Extended-release depot injections/implants (multi-patent formulation and manufacturing packages)
• Sublingual combination films (mucoadhesion, dose uniformity, and excipient system patents)
• Abuse-deterrent variants (mechanical/chemical deterrence mechanisms)

Decision-use detail:

• Patent density matters more than total patents when patents are “independent claims” that cannot be bypassed by route/formulation changes.
• For strategy, categorize patents by whether a generic must match product-specific PK/functional endpoints tied to the protected formulation system.

---

What Paragraph IV challenges have targeted POAA products and where do generic entry risks concentrate?

POAA Paragraph IV risk concentrates where:

• patents are recently issued on formulation/manufacturing for ER products;
• patents cover dose-form specific ADF features; or
• the listed patents are method-of-use tied to dosing regimens that generic labels do not automatically replicate.

Litigation outcomes for POAAs typically influence:

• whether a generic ships at risk,
• whether settlements lead to a delayed launch date (often tied to a subset of patents),
• and whether authorized generics appear.

Common settlement structures in POAA disputes

• Delayed launch date matching the earliest non-expired asserted patent or a chosen “carve-out” subset.
• Co-promotion/royalty or revenue share arrangements are less common for older buprenorphine film/tablet products but appear in some later-gen ER and ADF disputes.
• Design-around agreement: generics agree to not market a formulation that triggers infringement.

---

Which POAA patents have strong “design-around” barriers: formulation, ADF, or method-of-use?

For business risk scoring, classify each patent family by its enforceability leverage:

• Formulation/ADF: generally strong if the generic must replicate specific excipient matrices, particle-engineering parameters, or deterrence-mechanism performance.
• ER depot: strong when claims tie to geometry, release kinetics, and polymer composition, limiting straightforward “same molecule, different matrix” substitutions.
• Method-of-use: moderate strength when the generic can change labeling and still comply with statutory carve-outs; strong if labeling is difficult to avoid due to clinical standard-of-care and FDA label constraints.

Design-around is usually easiest for:

• older oral tablets without complex ADF mechanisms,
• products where the protected invention is broad (allowing alternative formulations),
• and patents that are narrow to a dosing regimen that can be omitted from the generic label.

---

How does FDA regulatory status affect POAA competitive timelines (505(b)(2), ANDA, and labeling carve-outs)?

Competition timing is driven by the FDA approval pathway:

• ANDA for generic copies of approved buprenorphine and buprenorphine/naloxone products depends on bioequivalence and is tightly linked to Orange Book challenges.
• 505(b)(2) can introduce a new reference, potentially changing patent listing exposure if a different RLD is used.
• Labeling carve-outs affect method-of-use infringement risk. For POAAs, label wording can become the battleground because OUD dosing instructions are often standardized.

Regulatory friction points:

• REMS applicability and distribution controls can slow generic uptake after legal entry.
• Manufacturing validation cycles and supply chain readiness shape real-world launch speed.

---

How do extended-release depot partial opioid agonist antagonists compare with sublingual buprenorphine in patent strength?

Depot/ER POAAs usually have the strongest and most litigation-relevant patent estates due to:

• multi-variable formulation systems,
• device or delivery-system claims,
• and performance-based PK/release characteristics.

Sublingual buprenorphine and buprenorphine/naloxone tablets/films typically face:

• earlier generic adoption for many strengths,
• but persistent brand strength where ADF or specific excipient/particle technologies remain protected.

Business implication:

• Depot products generally see fewer rapid generic waves because design-around is harder and because patent estates are broader and newer.
• Sublingual products can see multiple generic entrants after the earliest patent cliffs, with price pressure continuing until the last meaningful formulation patent expires.

---

What generic entry scenarios are most realistic for POAA companies after a patent cliff?

Realistic entry scenarios by product type:

Sublingual tablets and films

• Scenario A: full generic after last relevant Orange Book patent expires or after Paragraph IV resolves.
• Scenario B: partial carve-outs where generic is permitted but only if infringement is avoided by labeling and/or formulation differences.

Depot and ER injections

• Scenario C: delayed entry via settlement with launch aligned to a later expiring formulation or ADF patent.
• Scenario D: at-risk launch if patent litigation is resolved quickly or if asserted patents are narrowed or found invalid/not infringed.
• Scenario E: slower market penetration due to manufacturer scale-up and supply constraints, even after legal entry.

---

Which companies are most exposed in POAA patent litigation and settlements?

POAA exposure usually concentrates among:

• Originator brands that rely on depot/ADF extensions to defend revenue.
• Large generic filers seeking early ANDA launches through Paragraph IV challenges.
• Specialty generics and authorized generic partners that can match supply and distribution.

Where litigation is active, track:

• settlement-driven delayed launch dates,
• whether generics are authorized to market “at” or “after” a specific patent expiration,
• and whether settlement includes an agreed design-around.

---

Key POAA market dynamics: payer, adherence, and product switching between buprenorphine and naltrexone

Even when patents expire, market behavior can lag. POAA switching is shaped by:

• adherence drivers: monthly depot dosing can displace daily/film therapies;
• payer preference and prior authorization requirements;
• clinician habits and patient stabilization constraints;
• REMS and distribution controls.

Commercially, this means:

• patent cliffs affect legal entry, but payer and access conditions determine uptake and revenue recovery.
• extended-release products can maintain share even with legal generic entry if clinician switching is slow.

---

Key Takeaways

• POAAs are dominated by buprenorphine (including buprenorphine/naloxone) and extended-release/depot delivery innovations where patent estates are formulation- and performance-driven.
• Competitive timing hinges on the “last relevant Orange Book patent” for each dosage form, not the earliest composition-of-matter patent.
• Paragraph IV risk concentrates in ER/depot and abuse-deterrent families where design-around is difficult and patent breadth is higher.
• FDA pathway and labeling carve-outs (especially for method-of-use patents) are decisive in determining whether a generic can launch and what label it can use.
• Market uptake after legal entry can remain slower than patent expiry due to payer controls, REMS/distribution, and clinician switching behavior.

---

FAQs

1) What patent types most often block generic buprenorphine/naloxone sublingual films?

Formulation patents tied to film excipient systems, mucoadhesion performance, and any ADF-related structural features most often drive non-infringement difficulty for near-copies.

2) What causes the “last patent” for depot buprenorphine to expire later than expected?

Late-listed formulation, manufacturing/process-control, and ER release-performance patents commonly extend the practical exclusivity cliff beyond early composition-of-matter dates.

3) How do labeling carve-outs affect method-of-use patent exposure for OUD?

If a generic can avoid using infringing dosing language and the FDA label supports a non-infringing regimen, method-of-use risk can drop sharply; if standard regimens are hard to avoid, exposure stays higher.

4) Do REMS and distribution controls delay generic uptake after patent expiry?

Yes. Legal launch can occur, but slow channel onboarding, payer prior authorization, and distribution readiness can delay real-world adoption.

5) Are naltrexone products more or less patent-protected than buprenorphine POAAs?

In many cases, older oral naltrexone has less recent formulation-intensive patent coverage, while extended-release injectable formats tend to concentrate more robust formulation and device-delivery IP.

---

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. FDA.
2. U.S. Food and Drug Administration. Drug Approval Reports and approval letters (ANDA/505(b)(2) submissions). FDA.
3. U.S. Patent and Trademark Office. Patent assignment and prosecution data (assignee and legal status records). USPTO.
4. FDA Guidance Documents on 505(b)(2) and ANDA regulatory framework and labeling considerations. FDA.